CDK2 and neoplasm: Second, tumor cells with high CCND1 and activated PI3K can adapt to palbociclib via non-canonical binding of CDK2 to CCND1,53 and Bx2 had higher CCND1 protein levels (1.7× versus Bx1) and PI3K/AKT signaling than Bx1.